Latest atopic dermatitis Stories
ANTONY, France, June 21, 2010 /PRNewswire-FirstCall/ -- Stallergenes S.A. announces the results of a phase III clinical trial (VO55.06) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy (Staloral(R) mites 300) in adult patients suffering from asthma triggered by house dust mites. Study VO55.06 is a phase III randomized, double-blind, placebo-controlled study conducted over a period of 15 months in 14 centers located in China's main cities.
GENEVA, May 20, 2010 /PRNewswire/ -- - Expert Tips for Parents of Children With Eczema Several leading European dermatologists have today launched guidance to help parents reduce the burden of eczema on children living with this disease.
RALEIGH, N.C., March 9 /PRNewswire/ -- Arbor Pharmaceuticals ("Arbor"), a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched Pediaderm(TM) HC Complete Kit - an innovative new product for the comprehensive management of atopic dermatitis.
-- Gene Linked to Eosinophilic Esophagitis Plays Key Role in Inflammation-- PHILADELPHIA, March 8 /PRNewswire-USNewswire/ -- Pediatrics researchers have identified the first major gene location responsible for a severe, often painful type of food allergy called eosinophilic esophagitis (EoE).
Gene linked to eosinophilic esophagitis plays key role in inflammation.
Dermatologists can help identify allergens linked to this skin condition MIAMI, March 4 /PRNewswire-USNewswire/ -- Itchy irritated skin can leave some people scratching their heads trying to determine the cause of this bothersome condition.
REHOVOT, Israel, and SAN DIEGO, California, March 3, 2010 /PRNewswire/ -- Foamix Ltd., (Foamix), a leading developer of topical foams for dermatological and gynecological use, and Therapeutics Inc.
Allergies and asthma are a continuing health problem in most developed countries, but just how do these ailments develop over the course of a childhood?
LUND, Sweden, December 2 /PRNewswire/ -- DermaGen AB - part of the Karolinska Development dermatology and wound healing company "Pergamum" - today announced that Dermagen AB has received promising results from a clinical Phase I/IIa study.
Scientists of Helmholtz Zentrum MÃ¼nchen and the Center of Allergy and Environment (ZAUM) of Technische UniversitÃ¤t MÃ¼nchen have discovered a new type of immune cells - the Th22 cells - which can protect the body against inflammation and aid in tissue repair.
- totally perplexed and mixed up.